VASRO Research Highlights Ainos' Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset

Rhea-AI Summary

Ainos (NASDAQ:AIMD) announced that research firm VASRO highlighted the company’s progress in scaling its AI Nose platform through semiconductor deployments, real-world data accumulation, and commercialization into the second half of 2026. According to VASRO, AI Nose has gathered about 613 million industrial Smell ID data records since December 2025, mainly from semiconductor manufacturing.

VASRO cites a $2.1 million AI Nose subscription backlog from a backend semiconductor customer, including roughly $350,000 prepaid, plus ongoing validation in front-end fabs. The report views the expanding deployment footprint, dataset growth, and commercial commitments as constructive indicators for broader Smell AI adoption and potential revenue growth.

Positive

• $2.1 million AI Nose subscription backlog from a backend semiconductor customer
• Approximately $350,000 of the AI Nose subscription backlog already prepaid by the customer
• AI Nose has accumulated around 613 million industrial Smell ID data records since December 2025
• VASRO highlights expanding deployments and validation across semiconductor fabs as supporting broader Smell AI commercialization

Negative

• None.

Market Context

The AI-tagged history averaged 0.69% across five events. This report’s commercialization claims can ...

Analysis

The AI-tagged history averaged 0.69% across five events. This report’s commercialization claims can be weighed against that mixed record; current Net Selling insider activity was a separate risk factor, while short positioning was low.

Key Figures

Smell ID data records: approximately 613 million records AI Nose subscription backlog: $2.1 million Customer prepayment: approximately $350,000 +2 more

5 metrics

Smell ID data records approximately 613 million records Accumulated since December 2025, primarily in semiconductor manufacturing

AI Nose subscription backlog $2.1 million Backend semiconductor customer

Customer prepayment approximately $350,000 Prepaid within the AI Nose subscription backlog

Detection sensitivity ppb-level AI Nose scent detection, subject to application conditions and deployment configurations

Accumulated scent data history more than a decade Data supporting the AI Nose platform

Previous AI Reports

5 past events · Latest: Aug 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 06	Research coverage	Positive	+7.8%	Zacks covered AI Nose and broader Smell AI expansion strategy
Jul 21	Dataset update	Positive	-1.9%	Industrial scent dataset reached approximately 613 million data points
Jun 22	Research update	Positive	+1.6%	VASRO highlighted expansion into patient-level breath intelligence
Jun 17	Research program	Positive	+8.5%	National Taiwan University launched a one-year breath-intelligence program
Jun 05	Operational expansion	Positive	-12.6%	VASRO reported expansion into live emergency department operations

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-tagged announcements showed mixed reactions, with three aligned positive moves and two divergences.

Key Terms

mems sensor arrays, ppb-level, semiconductor fabs

3 terms

mems sensor arrays technical

"The full-stack electronic nose platform integrates high-precision MEMS sensor arrays"

Microelectromechanical systems (MEMS) sensor arrays are collections of tiny mechanical sensors fabricated on semiconductor chips that measure physical quantities like motion, pressure, sound, or chemical signals. Like a band of miniature instruments working together, an array combines many small sensors to improve accuracy, sensitivity, or to detect different things at once; investors watch them because they drive features, cost, supply chain scale, and market opportunities in electronics, automotive, medical devices, and industrial IoT.

ppb-level technical

"designed to support ppb-level scent detection sensitivity"

ppb-level means a concentration measured in parts per billion, or one unit of a substance for every one billion units of the whole (1 in 1,000,000,000). It signals extremely small, trace amounts—like one second in about 31.7 years—and matters to investors because such low concentrations can determine regulatory compliance, product purity, environmental contamination, or liability exposure where tiny differences trigger costly tests, recalls, or permits.

semiconductor fabs technical

"ongoing validation activities in front-end semiconductor fabs"

Semiconductor fabs are specialized factories where computer chips are built using tightly controlled cleanrooms and precision equipment to pattern, etch and assemble tiny electronic circuits onto silicon wafers. They matter to investors because fabs are extremely capital- and expertise-intensive, determine how many chips a company can make and how quickly, and therefore influence revenue, margins and supply risk—think of a fab as the high-tech bakery that produces a firm’s core product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, TX / ACCESS Newswire / August 10, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced VASRO GmbH has published a new report discussing Ainos' progress in scaling its AI Nose platform through semiconductor deployments, real-world data accumulation, and commercialization opportunities into the second half of 2026.

VASRO notes that AI Nose has accumulated approximately 613 million industrial Smell ID data records since December 2025, primarily from semiconductor manufacturing environments. The report views this rapidly expanding real-world dataset as a core strategic asset that strengthens Ainos' Smell AI capabilities, enhances the platform's ability to recognize environmental patterns, and builds a broader data foundation for scaling the platform across additional industrial applications.

VASRO also discusses Ainos' $2.1 million AI Nose subscription backlog from a backend semiconductor customer, including approximately $350,000 prepaid by the customer, alongside ongoing validation activities in front-end semiconductor fabs. The report views these commercial commitments and validation programs as evidence of growing customer traction and a broader opportunity to scale across the semiconductor value chain, while supporting potential revenue growth in the second half of 2026.

Overall, VASRO views Ainos' expanding deployment footprint, growing Smell ID dataset, and existing commercial commitments as constructive indicators of the Company's progress toward broader Smell AI adoption and commercialization.

The full VASRO report is available here:
https://vasro.de/wp-content/uploads/2026/08/VASRO-GmbH_Update_Report_Ainos_Inc_08072026_EN.pdf

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.

Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.

About Ainos, Inc.

Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA^®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. Visit media room https://ainos.suite.accessnewswire.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact Information
Investor Relations
ir@ainos.com

SOURCE: Ainos, Inc.

View the original press release on ACCESS Newswire

FAQ

What did the VASRO research report highlight about Ainos (NASDAQ:AIMD) on August 10, 2026?

VASRO highlighted Ainos’ progress scaling its AI Nose platform in semiconductor environments and building a large Smell ID dataset. According to Ainos, the report views the deployment footprint, data accumulation, and commercial commitments as constructive for broader Smell AI adoption and potential revenue growth into the second half of 2026.

How large is Ainos’ AI Nose subscription backlog mentioned in the VASRO report for AIMD?

The AI Nose subscription backlog totals about $2.1 million from a backend semiconductor customer. According to Ainos, approximately $350,000 of this amount has been prepaid, and the report sees these commitments as evidence of customer traction and a foundation for potential revenue growth in late 2026.

How many Smell ID data records has Ainos’ AI Nose platform accumulated as of the VASRO update?

AI Nose has accumulated roughly 613 million industrial Smell ID data records since December 2025. According to Ainos, these records come mainly from semiconductor manufacturing environments and are viewed by VASRO as a core strategic asset strengthening Smell AI capabilities and supporting scaling across more industrial applications.

How does the VASRO report describe commercialization prospects for Ainos’ AI Nose in the semiconductor sector?

VASRO describes commercialization prospects as supported by the AI Nose subscription backlog and ongoing fab validations. According to Ainos, the report sees these commercial commitments and validation programs as indicating growing customer traction and a broader opportunity to scale across the semiconductor value chain in the second half of 2026.

What is Ainos’ AI Nose platform and Smell ID technology mentioned in the VASRO research on AIMD?

AI Nose is a full-stack electronic nose that digitizes scent into machine-readable Smell ID data. According to Ainos, it integrates MEMS sensor arrays with proprietary AI, including a Smell Language Model designed to learn and contextualize complex scent patterns for monitoring, predictive analysis, and real-time alerts in industrial settings.

What business model does Ainos use to commercialize its AI Nose Smell AI platform?

Ainos commercializes AI Nose under a SmellTech-as-a-Service subscription model. According to Ainos, this architecture is intended to provide ongoing access to scent intelligence, analytics, and AI-driven insights, supporting continuous monitoring and predictive capabilities across industrial and manufacturing environments for customers adopting the platform.